Treatments for dry eye and ocular allergy typically are directed at symptoms. Researchers have begun developing therapeutics to target the causes of dry eye and to prevent the allergic reaction.
The hygiene hypothesis suggests that smaller family sizes as well as the use of antibiotics and vaccines has led to an allergy epidemic. Probiotics could reverse that epidemic and reduce the risk of developing atopic diseases and, potentially, nasal and ocular symptoms of respiratory allergies.
Ocular symptoms of allergies for many are as severe as rhinitis symptoms said Stephen C. Pflugfelder, MD. Ocular manifestations of seasonal allergies include seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), and atopic keratoconjunctivitis (AKC), said Dr. Pflugfelder. The ideal therapy should include multiple steps in the allergy cascade, perhaps by neutralizing both the H1 and H2 receptors, stabilizing the mast cells, and having anti-inflammatory properties.
Durham, NC—Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.’s 1% azithromycin topical anti-infective product (AzaSite) in the United States and Canada under the terms of a licensing agreement signed by the two companies. The product is under new device application review by the FDA for the treatment of bacterial conjunctivitis.
Irvine, CA—ISTA Pharmaceuticals Inc. plans to file a supplemental new drug application with the FDA later this year based on preliminary results and pending further analyses of a phase III trial of its once-daily formulation of bromfenac sodium ophthalmic solution (Xibrom). If approved, this formulation of the topical non-steroidal anti-inflammatory drug (NSAID) would become the only once-daily treatment for ocular pain and inflammation after cataract surgery.
An international phase III study is well under way evaluating the efficacy and safety of an innovative intravitreal insert of fluocinolone acetonide (Medidur, Alimera Sciences and Psivida Inc.) for the treatment of diabetic macular edema (DME).
Preferential hyperacuity perimetry (PHP; Foresee PHP, Notal Vision/ MSS) is innovative diagnostic technology uniquely able to detect the progression of age-related macular degeneration (AMD) from the intermediate stage to neovascular disease, according to Michael Elman, MD.
Baltimore—Results from the Amblyopia Treatment Study 3 (ATS3) support offering amblyopia treatment to children aged 7 to 12 years and considering it as well for children aged as many as 17 years who have not been treated previously, reported Michael X. Repka, MD, at the Current Concepts in Ophthalmology meeting here.